NewsEvents

Your Yourlocation: Home > To observe the improvement of tiotropium bromide(136310-93-5) on lung function

Shijiazhuang Medical College Jilian campus hospital Zhang Linghui et al studied the Eucalyptus leptin combined with tiotropium bromide(136310-93-5) in the treatment of acute exacerbation of chronic obstructive pulmonary disease clinical observation, the study found that eucalyptus leptin combined with tiotropium in the treatment of chronic obstructive Lung disease, acute exacerbation of a significant effect, safe and reliable, worthy of clinical use. The article published in 2016 02 issue of "Clinical Journal of rational drug use".

The aim of this study was to observe the clinical efficacy of tiotropium bromide(136310-93-5) combined with eucalyptus citri reticulata enteric-coated soft capsule in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD).

METHODS: A total of 82 patients with acute exacerbations of chronic obstructive pulmonary disease were enrolled in the study from July 2012 to September 2014 and were randomly divided into trial and control groups (n = 41). 2 groups of patients were oxygen, antispasmodic asthma, anti-infective therapy. The test group was treated with tiotropium bromide(136310-93-5) combined with eucalyptus citri reticulata enteric-coated soft capsule. The control group was treated with oral ampicillin hydrochloride for 7 days. After 1 course of treatment, the clinical efficacy, average length of hospital stay and improvement of dyspnea were compared.

The results showed that the total effective rate was 97.56% in experimental group was significantly higher than 85.37% in the control group; the average length of stay in the test group shorter than the control group, the total improvement rate of 100.0% dyspnea was significantly higher than the control group 87.8%, the difference was statistically (P <0.05).

We have tremendous progress in the understanding of COPD. Specifically we looked into the case of long acting anti cholinergic like tiotropium bromide(136310-93-5), we have over 35 million patients years of experience to the medication, and we have landmark trials like UPLIFT, 4-year-study in lung function effect, and we have studies comparing LABA and LAMA in the effect of exacerbations like POET, and we have study in patients’ management and assessment like TIOSPIR with over 17000 patients with moderate of severe COPD willing to participate.

These tremendous experiments have shown the development of clinical trials and in the understanding of how the medications work.

Tiotropium bromide(136310-93-5) was approved in the some countries around 11-12 years ago and we have nearly 200 clinical trials to evaluate the different aspects how the medication impacts COPD and the studies also have shown that the medication is associated with significant improvement in lung function, significant improvement in exercise capacity and quality of life, and at the same time have reduction in exacerbations, hospitalizations and someday we suggest in mortality.


Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved